Publication:
New therapeutics to treat castrate-resistant prostate cancer

Simple item page
dc.contributor.kuauthorAcar, Ömer
dc.contributor.kuauthorEsen, Tarık
dc.contributor.kuauthorLack, Nathan Alan
dc.contributor.kuprofileFaculty Member
dc.contributor.kuprofileFaculty Member
dc.contributor.kuprofileFaculty Member
dc.contributor.schoolcollegeinstituteSchool of Medicine
dc.contributor.yokid237530
dc.contributor.yokid50536
dc.contributor.yokid120842
dc.date.accessioned2024-11-09T13:18:41Z
dc.date.issued2013
dc.description.abstractThe effective treatment of castrate-resistant prostate cancer (CRPC) has proven to be very challenging. Until recently, docetaxel was the only therapeutic demonstrated to extend overall patient survival. Yet recently, a considerable number of new therapeutics have been approved to treat CRPC patients. These remarkable advances now give new tools for the therapeutic management of late-stage prostate cancer. In this review, we will examine mechanistic and clinical data of several newly approved therapeutics including the chemotherapeutic cabazitaxel, antiandrogen enzalutamide, endocrine disruptor abiraterone acetate, immunotherapy sipuleucel-T, and bone-targeting radiopharmaceutical alpharadin. In addition, we will examine other promising therapeutics that are currently in Phase III trials.
dc.description.fulltextYES
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipN/A
dc.description.versionPublisher version
dc.description.volume2013
dc.formatpdf
dc.identifier.doi10.1155/2013/379641
dc.identifier.eissn1537-744X
dc.identifier.embargoNO
dc.identifier.filenameinventorynoIR00050
dc.identifier.linkhttps://doi.org/10.1155/2013/379641
dc.identifier.quartileN/A
dc.identifier.scopus2-s2.0-84879309107
dc.identifier.urihttps://hdl.handle.net/20.500.14288/3024
dc.identifier.wos320253500001
dc.keywordsHuman cytochrome p450(17-alpha)
dc.keywordsDocetaxel plus prednisone
dc.keywordsMetastatic breast-cancer
dc.keywordsAdvanced solid tumors
dc.keywordsRandomized phase-ii
dc.keywordsSipuleucel-t
dc.keywordsSteroidal inhibitors
dc.keywordsAntisense oligonucleotide
dc.languageEnglish
dc.publisherHindawi
dc.relation.urihttp://cdm21054.contentdm.oclc.org/cdm/ref/collection/IR/id/1082
dc.sourceThe Scientific World Journal
dc.subjectMedicine
dc.subjectScience and technology
dc.titleNew therapeutics to treat castrate-resistant prostate cancer
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.authorid0000-0002-6094-9264
local.contributor.authorid0000-0002-0961-9374
local.contributor.authorid0000-0001-7399-5844
local.contributor.kuauthorAcar, Ömer
local.contributor.kuauthorEsen, Tarık
local.contributor.kuauthorLack, Nathan Alan

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
1082.pdf
Size:
609.14 KB
Format:
Adobe Portable Document Format
Download

Collections

Publications with Fulltext